IVF形成胚胎仍可施行胚胎切片& PGT

• 精子 DNA 在 Picoplex 和 ChromInst 條件下無法擴增，但可以使用 MDA 進行擴增。
• 在冷凍 PGT-A 週期中，cIVF-PGT-A 組和 ICSI-PGT-A 組之間每個週期的整倍體、嵌合體和非整倍體胚胎的平均速率沒有顯著差異。
• 夫妻接受 cIVF-PGT-A 治療的前瞻性研究結果顯示，在 150 個活檢滋養外胚層樣本中，沒有出現父源污染，只有 1 個母源污染。

• Sperm DNA failed to amplify under Picoplex and ChromInst conditions but could be amplified using MDA. 
• In frozen PGT-A cycles, no significant differences in the average rates of euploid, mosaic, and aneuploid embryos per cycle between the cIVF-PGT-A and ICSI-PGT-A groups were observed.
• The results of the prospective study that recruited couples for cIVF-PGT-A treatment showed no paternal contamination and one case of maternal contamination in 150 biopsied trophectoderm samples. 

. 2023 Oct;40(10):2333-2342.

 doi: 10.1007/s10815-023-02916-7. Epub 2023 Sep 1.

Conventional IVF is feasible in preimplantation genetic testing for aneuploidy

Purpose: To investigate the feasibility of the application of conventional in vitro fertilization (cIVF) for couples undergoing preimplantation genetic testing for aneuploidies (PGT-A) with non-male factor infertility.

Methods: To evaluate the efficiency of sperm whole-genome amplification (WGA), spermatozoa were subjected to three WGA protocols: Picoplex, ChromInst, and multiple displacement amplification (MDA). In the clinical studies, 641 couples who underwent PGT-A treatment for frozen embryos between January 2016 and December 2021 were included to retrospectively compare the chromosomal and clinical outcomes of cIVF and intracytoplasmic sperm injection (ICSI). Twenty-six couples were prospectively recruited for cIVF and PGT-A treatment between April 2021 and April 2022; parental contamination was analyzed in biopsied samples; and 12 aneuploid embryos were donated to validate the PGT-A results.

Results: Sperm DNA failed to amplify under Picoplex and ChromInst conditions but could be amplified using MDA. In frozen PGT-A cycles, no significant differences in the average rates of euploid, mosaic, and aneuploid embryos per cycle between the cIVF-PGT-A and ICSI-PGT-A groups were observed. The results of the prospective study that recruited couples for cIVF-PGT-A treatment showed no paternal contamination and one case of maternal contamination in 150 biopsied trophectoderm samples. Among the 12 donated embryos with whole-chromosome aneuploidy, 11 (91.7%) presented uniform chromosomal aberrations, which were in agreement with the original biopsy results.

Conclusions: Under the Picoplex and ChromInst WGA protocols, the risk of parental contamination in the cIVF-PGT-A cycles was low. Therefore, applying cIVF to couples with non-male factor infertility who are undergoing PGT-A is feasible.